You are currently viewing Jo Varshney, VeriSIM CEO, Finalist for 2023 Stevie® Awards for Women in Business

Jo Varshney, VeriSIM CEO, Finalist for 2023 Stevie® Awards for Women in Business

Sapna Srivastava Varshney, the Founder and CEO of VeriSIM Life, has been named a finalist in the “Most Innovative Woman of the Year—Healthcare” category of the 20th annual Stevie® Awards for Women in Business. The Stevie Awards recognize top women entrepreneurs, executives, employees, and organizations worldwide.

Varshney is one of seven finalists in the “Most Innovative Woman of the Year—Healthcare” category, alongside other healthcare leaders. This year’s awards received over 1,600 nominations in 100 categories.

VeriSIM Life is known for its work in developing the world’s first “credit score” for de-risking drug development, which involves the innovative use of artificial intelligence (AI) and machine learning (ML) techniques. The company’s technology uses AI and ML to create a “credit score” for drug development, significantly reducing the risk of errors and failures in the drug research process, improving clinical trial success rates, and reducing time-to-market for new therapeutics.

Varshney expressed her gratitude for being selected as a finalist and acknowledged her talented team for driving innovations in the healthcare industry. The winners of the Gold, Silver, and Bronze awards will be announced during the Stevie Awards gala on November 10, 2023, in New York City.

The Stevie Awards were established in 2002 to recognize the achievements and contributions of organizations and professionals worldwide through a series of eight awards programs.

VeriSIM Life is a company that has developed an advanced computational platform, BIOiSIM®, which leverages AI and ML techniques to streamline drug discovery and development processes, ultimately reducing costs and time to market.

This recognition highlights Sapna Srivastava Varshney’s leadership and the significant impact of VeriSIM Life’s technology in the healthcare sector. The platform has the potential to revolutionize drug development and bring innovative therapies to market more efficiently.

Leave a Reply